Biotech: Page
-
Permission granted by Greater Phoenix Economic Council (GPEC)
Sponsored by Greater Phoenix Economic Council (GPEC)Why bioscience and healthcare innovators are looking to Phoenix
When Mayo Clinic was evaluating locations to build a biotechnology innovation hub, the Greater Phoenix region emerged as the ideal option.
Dec. 9, 2024 -
Michael M. Santiago via Getty Images
BioAge shares tumble after decision to halt obesity drug study
The biotech disclosed Friday plans to terminate a Phase 2 study testing azelaprag with tirzepatide for weight loss following safety concerns.
By Gwendolyn Wu • Dec. 7, 2024 -
Explore the Trendline➔
National Institutes of Allergy and Infectious Diseases. (2016). "Human natural killer cell" [Micrograph]. Retrieved from Flickr.
TrendlineCell therapy
The continued emergence of CAR-T therapy has fueled research into next-generation approaches and new applications, such as its use in autoimmune diseases or in reprogramming cells inside the body.
By BioPharma Dive staff -
Getty Images
AstraZeneca, Daiichi build cancer drug case; Amgen invests $1B
The two partners disclosed study results supporting an approval application for their drug dato-dxd. Elsewhere, Agenus cut spending and the U.S. PTO withdrew a controversial proposed patent rule.
By BioPharma Dive staff • Dec. 6, 2024 -
Permission granted by Atlas Venture
Atlas doubles down on ‘disciplined’ biotech investing with latest fundraise
The venture firm’s “modest” $450 million fund, a lower total than some of its peers recently raised, reflects lessons learned after Atlas grew too quickly, partner Bruce Booth wrote in a blog post.
By Kristin Jensen • Dec. 5, 2024 -
Courtesy of GSK
GSK taps a startup for shot at Alzheimer’s drug
The collaboration deal, which could be worth hundreds of millions of dollars, is a “pivotal moment” for Muna Therapeutics, a startup that launched less than four years ago.
By Jacob Bell • Dec. 5, 2024 -
Permission granted by Nuvig Therapeutics
Nuvig pulls in $161M to make better immune drugs
The company is developing treatments to rebalance, rather than suppress, immune function in people with inflammatory conditions, starting with an antibody near Phase 2 testing.
By Gwendolyn Wu • Dec. 5, 2024 -
Getty Images
Atea plans Phase 3 study for hepatitis C drug after mid-stage results
The struggling biotech company is looking to break into the lucrative hepatitis C market with the promise of an easier treatment regimen.
By Kristin Jensen • Dec. 4, 2024 -
Getty Images
Novavax sells Czech plant to Novo; Relay licenses out a cancer drug
Novo will pay $200 million to gain control of the protein manufacturing factory. Elsewhere, Roivant dropped a drug program and Takeda acquired a blood disease therapy.
By BioPharma Dive staff • Dec. 4, 2024 -
Permission granted by Antag Therapeutics
Antag, a startup backed by Versant and Novo, joins hunt for obesity drug alternatives
The company, which raised $84 million, sees validation of its GIP-blocking approach to weight loss in Amgen's recent MariTide drug data.
By Jonathan Gardner • Dec. 4, 2024 -
Getty Images
Janux impresses Wall Street with new prostate cancer drug results
While early and from a small trial, the findings suggest Janux’s method of “masking” T cell engagers could lead to differentiated results, some analysts said.
By Ben Fidler • Dec. 3, 2024 -
Getty Images
Coherus, sharpening immuno-oncology focus, sells another biosimilar for over $500M
The company reached a deal to divest its third biosimilar this year, selling a copycat version of Amgen’s Neulasta for up to $558 million.
By Delilah Alvarado • Dec. 3, 2024 -
Getty Images
Novocure device succeeds in pancreatic cancer study; FDA sets Cytokinetics decision date
Using tumor-treating fields alongside chemotherapy improved patient survival, Novocure said. Elsewhere, Cytokinetics got a key PDUFA date and Fate Therapeutics swapped CEOs.
By BioPharma Dive staff • Dec. 2, 2024 -
Kevin Dietsch / Staff via Getty Images
Pharma hopes Trump will bring change to the FTC. They may be disappointed.
Some in the drug industry expect more lenient merger enforcement under a second Trump administration. One former regulator argues that might not be the case.
By Kelly Bilodeau • Nov. 27, 2024 -
Getty Images
Q&A // Brain drug revivalHow Intra-Cellular surprised Wall Street by breaking character
The biotechnology company, which sees itself as "pretty conservative," recently put out an ambitious long-term revenue forecast for its schizophrenia and depression medicine Caplyta.
By Jacob Bell • Nov. 27, 2024 -
Getty Images
Kronos, Idorsia plan layoffs; PTC shelves ALS drug
Kronos is cutting 83% of its workforce, while Idorsia is considering eliminating as many as 270 jobs. Elsewhere, PTC disclosed negative Phase 2 results for its ALS drug candidate utreloxastat.
By BioPharma Dive staff • Nov. 27, 2024 -
Courtesy of Biohaven Ltd.
Biohaven muscle drug misses goal of SMA study, but advances in obesity
The setback likely removes one competitor to an emerging spinal muscular atrophy medicine from Scholar Rock, but sets the stage for a pair of readouts with implications for weight loss research.
By Ben Fidler • Nov. 25, 2024 -
Getty Images
BridgeBio heart drug approved by FDA, setting up battle with Pfizer
BridgeBio shares climbed by nearly 25% Monday on news its drug for a cardiac form of transthyretin amyloidosis was approved with a broad label that looks competitive to Pfizer's tafamidis.
By Ben Fidler • Nov. 22, 2024 -
Getty Images
Halozyme drops Evotec buyout bid; Patient dies in Neurogene trial
Evotec appears to have rebuffed Halozyme’s $2.1 billion acquisition attempt. Elsewhere, Argenx has another blockbuster target in sight and an FDA veteran plans retirement.
By BioPharma Dive staff • Nov. 22, 2024 -
Getty Images
Lexicon to disband sales team, lay off 60% of staff
The restructuring follows the company's receipt of a letter from the FDA citing "deficiencies" in its approval application for diabetes drug Zynquista.
By Ned Pagliarulo • Nov. 22, 2024 -
Adeline Kon/BioPharma Dive/BioPharma Dive
Deep Dive // Emerging biotechBiotech startups are built on venture capital. Track funding rounds here.
Six biotechs raised over $700 million in combined venture funding this week, though two of those companies — Solstice Oncology and Encoded Therapeutics — accounted for the bulk of the total.
By Gwendolyn Wu , Ben Fidler , Ned Pagliarulo , Julia Himmel • Updated Sept. 11, 2026 -
Jacob Bell/BioPharma Dive
Amgen picks prolific biotech founder Chang as new top scientist
Howard Chang will take over as chief scientific officer and senior VP of research as the biotech searches for more ways to overcome the looming loss of exclusivity for some of its top-selling medicines.
By Kristin Jensen • Nov. 21, 2024 -
Permission granted by Versant Ventures
Versant startup sets out to make a new type of obesity drug
The startup, Pep2Tango, is combining four methods of accelerating weight loss into one medicine in the hopes of developing a treatment that can improve upon drugs like Wegovy and Zepbound.
By Gwendolyn Wu • Nov. 21, 2024 -
Getty Images
Sage’s string of research failures continues
Negative results from a Huntington’s trial add to a calamitous year for Sage, which last month decided to overhaul its research, reconfigure its executive team and lay off a third of its staff.
By Jacob Bell • Nov. 20, 2024 -
Permission granted by Valora Therapeutics
Chasing new ‘checkpoints,’ startup Valora emerges from a Nobel winner’s lab
Built around research by Stanford scientist Carolyn Bertozzi and MIT researcher Jessica Stark, Valora Therapeutics is designing drugs to target glyco-immune checkpoints.
By Gwendolyn Wu • Nov. 20, 2024 -
Permission granted by Flagship Pioneering
Flagship, Pfizer alliance yields two more startup deals
Pfizer will work with Ampersand Biomedicines and Montai Therapeutics to find drugs for obesity and lung cancer, respectively, adding to collaborations it previously formed with other Flagship startups.
By Gwendolyn Wu • Updated Nov. 20, 2024
Previous
